Ketaki M.
Senior Life Sciences Advisor
Open to offersNew to PlatformAbout
Ketaki M., PhD, is a strategic life sciences professional based in London with over a decade of experience in biomedical research, venture creation, and technology evaluation. Her expertise spans the integration of AI, microbiome science, and synthetic biology to develop translational science solutions. As the former Chief Scientific Officer & Co-founder of GutSee Health Ltd, she led commercialization strategies, securing £250k+ in funding and forming key partnerships with institutions like University College London. Her role as an Advisor at the same company includes shaping IP strategy and supporting R&D prioritization. At EdenBio, she spearheaded the development of AI/ML–enabled genome engineering platforms. Her work at Hybridex Biosciences involved designing CRISPR studies for cardiac treatments. In her previous tenure at the University of Washington, she contributed to pioneering cell-based therapies for heart failure. Beyond her professional endeavors, Ketaki actively engages in the research ecosystem as an Expert Reviewer for the European Commission and a mentor for Women in Advanced Therapies.
Experience
Advisor
GutSee Health Ltd · 2025 — PresentProvide guidance on diagnostics-led translational strategy and intellectual property positioning for a techbio company focused on AI, microbiome science, synthetic biology, and phage-based therapies. Assist in R&D prioritization and therapeutic development planning while advising on IP strategy, partnerships, and translational funding opportunities.Chief Scientific Officer & Co-founder
GutSee Health Ltd · 2024 — 2025Co-founded a biotech venture aimed at developing AI-enabled diagnostics associated with microbiome-based therapeutic approaches. Directed the commercialization strategy, which included responsibilities for IP positioning, licensing negotiations, and partnership development with biotechnology collaborators.Founder in Residence
Zinc VC · 2024 — 2024Evaluated potential early-stage ventures in diagnostics, therapeutics, and AI-enabled biotech platforms. Conducted market landscape analyses and scientific diligence while assessing technology defensibility and commercialization pathways to support investment committee decisions.Lead R&D Scientist
EdenBio · 2024 — 2024Led the development of a genome engineering platform powered by generative AI/ML technologies. Designed scalable CRISPR screening workflows and evaluated commercialization pathways for these genome engineering technologies.Program Lead – Consultant (Cardiac Diseases)
Hybridex Biosciences · 2023 — 2024Designed in-vivo CRISPR studies for cardiac therapeutic programs. Developed translational frameworks, which included creating disease models, establishing dosing strategies, and selecting biomarkers, while assessing preclinical feasibility and safety endpoints.Senior Fellow, Heart Regeneration Program (incubator: Sana Biotechnology)
University of Washington · 2018 — 2023Led the development of engineered cell-based therapies aimed at treating chronic heart failure within a translational research program that collaborated with Sana Biotechnology. Worked alongside the university’s Technology Transfer Office to facilitate invention disclosures and support patent filings.
Skills & Expertise
Education
- PhD in Molecular MedicineMedical University Graz · — — 2018
- MSc in Biomedical SciencesLondon Metropolitan University / University of Sheffield · — — 2012